Drugs / PRAX-628
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06840925 | Mar → May 2025 overdue | — | Praxis Precision Medicines | Not yet recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06908356 | Jan → Jul 2025 overdue | focal epilepsy, generalized epilepsy | Praxis Precision Medicines | Recruiting | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06999902 | Dec 2024 → Nov 2025 overdue | focal epilepsy | Praxis Precision Medicines | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRAX 628 | “This Phase 1, randomized, open-label, 2-way crossover clinical trial is designed to investigate the relative bioavailability, pharmacokinetics (PK), safety, and tolerability of...” NCT06840925 ↗4“Participants who meet all eligibility criteria will be randomized at Visit 1 (Day 1) to receive 20 mg of PRAX-628 for 6 weeks followed by 30 mg PRAX 628 for the remaining 6 weeks.” NCT06999902 ↗ |
| Route | Oral | “administered orally” NCT06840925 ↗ |